Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An update from 4basebio UK Societas ( (GB:4BB) ) is now available.
4basebio PLC has announced the exercise of EMI options by two employees, resulting in the issuance of 13,000 new ordinary shares at an exercise price of £1.18 per share, raising £15,340 in total. These shares are set to be admitted to trading on AIM, with the total number of ordinary shares in issue rising to 15,509,393. This development is significant for shareholders as it impacts the total voting rights and may require them to notify changes in their shareholding under the Financial Conduct Authority’s rules.
The most recent analyst rating on (GB:4BB) stock is a Buy with a £1600.00 price target. To see the full list of analyst forecasts on 4basebio UK Societas stock, see the GB:4BB Stock Forecast page.
More about 4basebio UK Societas
4basebio (AIM: 4BB) is an innovation-driven biotechnology company focused on accelerating the development of advanced therapy medicinal products (ATMPs) through its high-performance synthetic DNA products and non-viral, cell-targeting nucleic acid delivery platform. The company aims to become a market leader in the manufacture and supply of high-quality synthetic DNA products for research, therapeutic, and pharmacological use, as well as the development of target-specific non-viral vectors for efficient delivery of payloads in patients.
Average Trading Volume: 1,056
Technical Sentiment Signal: Hold
Current Market Cap: £152.4M
For a thorough assessment of 4BB stock, go to TipRanks’ Stock Analysis page.